Display options
Cite
Schallenberg S, Merkelbach-Bruse S, Buettner R. Lung cancer as a paradigm for precision oncology in solid tumours. Virchows Arch. 2017;471(2):221-233doi: 10.1007/s00428-017-2183-2.
Schallenberg, S., Merkelbach-Bruse, S., & Buettner, R. (2017). Lung cancer as a paradigm for precision oncology in solid tumours. Virchows Archiv : an international journal of pathology, 471(2), 221-233. https://doi.org/10.1007/s00428-017-2183-2
Schallenberg, Simon, et al. "Lung cancer as a paradigm for precision oncology in solid tumours." Virchows Archiv : an international journal of pathology vol. 471,2 (2017): 221-233. doi: https://doi.org/10.1007/s00428-017-2183-2
Schallenberg S, Merkelbach-Bruse S, Buettner R. Lung cancer as a paradigm for precision oncology in solid tumours. Virchows Arch. 2017 Aug;471(2):221-233. doi: 10.1007/s00428-017-2183-2. Epub 2017 Jul 20. PMID: 28730537.
Copy Download .nbib Format: NLM
Share it on

Virchows Arch. 2017 Aug;471(2):221-233. doi: 10.1007/s00428-017-2183-2. Epub 2017 Jul 20.

Lung cancer as a paradigm for precision oncology in solid tumours.

Virchows Archiv : an international journal of pathology

Simon Schallenberg, Sabine Merkelbach-Bruse, Reinhard Buettner

Affiliations

  1. Institute of Pathology, University Hospital and Center for Integrated Oncology Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
  2. Institute of Pathology, University Hospital and Center for Integrated Oncology Cologne, Kerpener Straße 62, 50937, Cologne, Germany. [email protected].

PMID: 28730537 DOI: 10.1007/s00428-017-2183-2

Abstract

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death in the western world. However, the combination of molecular genotyping and subsequent systematic treatment of decoded target structures is a prime example of precision oncology in solid tumours. In this review, current targets of approved therapeutics and potential targets in clinical and preclinical trials are outlined. Furthermore, immune checkpoint inhibitors, as promising new therapeutic options, which have already been applied successfully in cases of lung cancer, are introduced. A major issue of targeted treatment of lung tumours is the persistent development of resistance. The underlying mechanisms and established and potentially applicable alternative therapeutic approaches are described. In this process of precision oncology, immunohistochemistry, fluorescence in situ hybridization, and parallel sequencing are crucial diagnostic tools.

Keywords: Immune checkpoint inhibitors; Network Genomic Medicine; Non-small cell lung cancer; Resistance; TKI

References

  1. Cancer Sci. 2016 Jan;107(1):45-52 - PubMed
  2. N Engl J Med. 2015 Oct 22;373(17):1627-39 - PubMed
  3. Nature. 2014 Nov 27;515(7528):563-7 - PubMed
  4. Turk J Med Sci. 2016 Dec 20;46(6):1854-1861 - PubMed
  5. Mol Cancer Ther. 2014 Dec;13(12 ):2910-8 - PubMed
  6. J Clin Oncol. 2012 Mar 10;30(8):863-70 - PubMed
  7. Proc Natl Acad Sci U S A. 1987 Dec;84(24):9270-4 - PubMed
  8. Oncotarget. 2015 Sep 15;6(27):23905-16 - PubMed
  9. Mod Pathol. 2014 May;27(5):711-20 - PubMed
  10. Ann Oncol. 2015 Jul;26(7):1421-7 - PubMed
  11. Clin Cancer Res. 2003 Nov 1;9(14):5238-43 - PubMed
  12. Cancer Discov. 2016 Oct;6(10 ):1118-1133 - PubMed
  13. J Clin Oncol. 2013 Sep 20;31(27):3327-34 - PubMed
  14. Science. 2014 Oct 10;346(6206):256-9 - PubMed
  15. Ann Oncol. 2016 Sep;27 Suppl 3:iii25-iii34 - PubMed
  16. Cell. 2007 Dec 14;131(6):1190-203 - PubMed
  17. Clin Cancer Res. 2017 Jan 1;23 (1):204-213 - PubMed
  18. Genes Chromosomes Cancer. 2003 May;37(1):58-71 - PubMed
  19. J Clin Oncol. 2013 Jul 10;31(20):e341-4 - PubMed
  20. Sci Transl Med. 2012 May 30;4(136):136ra70 - PubMed
  21. J Thorac Oncol. 2014 Mar;9(3):295-306 - PubMed
  22. Clin Cancer Res. 2013 Aug 1;19(15):4040-5 - PubMed
  23. Science. 1994 Mar 4;263(5151):1281-4 - PubMed
  24. J Clin Oncol. 2012 Dec 10;30(35):4352-9 - PubMed
  25. Cancer Sci. 2008 Dec;99(12):2349-55 - PubMed
  26. N Engl J Med. 2014 Dec 4;371(23):2167-77 - PubMed
  27. Clin Cancer Res. 2010 Nov 15;16(22):5581-90 - PubMed
  28. Science. 2015 Apr 3;348(6230):124-8 - PubMed
  29. Oncotarget. 2016 Jun 14;7(24):36101-36114 - PubMed
  30. Ann Oncol. 2015 Oct;26(10):2073-8 - PubMed
  31. Transl Lung Cancer Res. 2016 Dec;5(6):695-708 - PubMed
  32. Nat Med. 2012 Feb 12;18(3):378-81 - PubMed
  33. J Thorac Oncol. 2015 Jul;10(7):1049-57 - PubMed
  34. Lung Cancer. 2012 Apr;76(1):123-7 - PubMed
  35. Semin Oncol. 2015 Oct;42 Suppl 2:S11-8 - PubMed
  36. Nat Med. 2013 Nov;19(11):1469-1472 - PubMed
  37. Cancer Res. 2011 Sep 15;71(18):6051-60 - PubMed
  38. Mod Pathol. 2016 Oct;29(10):1165-72 - PubMed
  39. Proc Natl Acad Sci U S A. 1990 Jun;87(12 ):4799-803 - PubMed
  40. N Engl J Med. 2010 Oct 28;363(18):1734-9 - PubMed
  41. Cancer Sci. 2016 Nov;107(11):1667-1676 - PubMed
  42. Cancer Discov. 2013 Jun;3(6):630-5 - PubMed
  43. Nat Commun. 2016 Jun 10;7:11815 - PubMed
  44. Clin Cancer Res. 2016 May 15;22(10 ):2351-8 - PubMed
  45. Eur J Cancer. 2010 Jul;46(10):1773-80 - PubMed
  46. J Clin Oncol. 2016 Oct 1;34(28):3375-82 - PubMed
  47. Lancet Oncol. 2012 Mar;13(3):239-46 - PubMed
  48. Cancer Discov. 2017 Apr;7(4):400-409 - PubMed
  49. Clin Cancer Res. 2013 Apr 15;19(8):2240-7 - PubMed
  50. J Clin Oncol. 2016 May 20;34(15):e141-4 - PubMed
  51. Cancer Res. 2005 Mar 1;65(5):1642-6 - PubMed
  52. Clin Cancer Res. 2015 Mar 15;21(6):1258-66 - PubMed
  53. Virchows Arch. 2016 Nov;469(5):489-503 - PubMed
  54. Cancer Discov. 2015 Aug;5(8):850-9 - PubMed
  55. J Mol Diagn. 2015 May;17(3):251-64 - PubMed
  56. Clin Cancer Res. 2013 Aug 1;19(15):4273-81 - PubMed
  57. Clin Cancer Res. 2012 Mar 1;18(5):1472-82 - PubMed
  58. J Thorac Oncol. 2009 Jan;4(1):5-11 - PubMed
  59. Clin Cancer Res. 2015 Jan 1;21(1):166-74 - PubMed
  60. Mol Cancer Res. 2009 Sep;7(9):1466-76 - PubMed
  61. Sci Rep. 2015 Sep 24;5:14447 - PubMed
  62. Cancer. 2005 Nov 15;104(10):2149-55 - PubMed
  63. J Mol Diagn. 2013 Jul;15(4):415-53 - PubMed
  64. Nat Rev Cancer. 2007 Mar;7(3):169-81 - PubMed
  65. N Engl J Med. 2014 Nov 20;371(21):1963-71 - PubMed
  66. Sci Transl Med. 2010 Dec 15;2(62):62ra93 - PubMed
  67. Sci Transl Med. 2012 Feb 8;4(120):120ra17 - PubMed
  68. N Engl J Med. 2016 Nov 10;375(19):1823-1833 - PubMed
  69. Nat Med. 2012 Feb 12;18(3):375-7 - PubMed
  70. J Thorac Oncol. 2016 Jan;11(1):e1-4 - PubMed
  71. Oncotarget. 2015 Mar 10;6(7):5182-94 - PubMed
  72. Cancer Sci. 2008 Nov;99(11):2280-5 - PubMed
  73. Cancer Discov. 2015 Oct;5(10):1049-57 - PubMed
  74. Oncologist. 2013;18(7):865-75 - PubMed
  75. J Thorac Oncol. 2013 May;8(5):e43-4 - PubMed
  76. Nat Rev Cancer. 2010 Feb;10(2):116-29 - PubMed
  77. Lancet Oncol. 2016 Jul;17 (7):984-993 - PubMed
  78. Mol Cancer Ther. 2016 Apr;15(4):628-39 - PubMed
  79. Am J Surg Pathol. 2013 Sep;37(9):1441-9 - PubMed
  80. Clin Cancer Res. 2016 Oct 1;22(19):4837-4847 - PubMed
  81. Ann Oncol. 2016 Sep;27(suppl 5):v1-v27 - PubMed
  82. Lung Cancer. 2015 Dec;90(3):465-71 - PubMed
  83. Ann Oncol. 2013 Sep;24(9):2371-6 - PubMed
  84. Clin Cancer Res. 2015 Aug 15;21(16):3631-9 - PubMed
  85. Nature. 2014 Jul 31;511(7511):543-50 - PubMed
  86. J Thorac Oncol. 2016 Jan;11(1):122-7 - PubMed
  87. Sci Transl Med. 2013 Oct 30;5(209):209ra153 - PubMed
  88. Clin Cancer Res. 2009 May 1;15(9):3143-9 - PubMed
  89. Cancer Discov. 2015 Jul;5(7):713-22 - PubMed
  90. Lung Cancer. 2017 Apr;106:110-114 - PubMed
  91. Clin Lung Cancer. 2015 Sep;16(5):e101-4 - PubMed
  92. J Clin Oncol. 2016 Aug 20;34(24):2866-73 - PubMed
  93. J Thorac Oncol. 2016 Apr;11(4):487-95 - PubMed
  94. Nat Med. 2014 Dec;20(12):1479-84 - PubMed
  95. Ann Oncol. 2004 Jan;15(1):19-27 - PubMed
  96. Lancet Oncol. 2016 May;17 (5):642-50 - PubMed
  97. Transl Lung Cancer Res. 2015 Feb;4(1):36-54 - PubMed
  98. N Engl J Med. 2015 Jul 9;373(2):123-35 - PubMed
  99. Cancer Cell. 2006 Jul;10(1):25-38 - PubMed
  100. Oncologist. 2015 Mar;20(3):316-22 - PubMed
  101. Eur Respir Rev. 2014 Sep;23(133):356-66 - PubMed
  102. JAMA. 2014 May 21;311(19):1998-2006 - PubMed
  103. J Clin Oncol. 2016 Mar 1;34(7):721-30 - PubMed
  104. Genes Chromosomes Cancer. 2016 Jan;55(1):30-44 - PubMed
  105. Clin Cancer Res. 2009 Sep 15;15(18):5714-23 - PubMed
  106. J Thorac Oncol. 2015 Dec;10 (12 ):1736-44 - PubMed
  107. Lancet Oncol. 2016 Feb;17 (2):234-242 - PubMed
  108. J Thorac Oncol. 2015 Dec;10 (12 ):1670-4 - PubMed
  109. J Clin Oncol. 2011 Sep 10;29(26):3574-9 - PubMed
  110. Cochrane Database Syst Rev. 2016 May 25;(5):CD010383 - PubMed
  111. Cancer Res. 2006 Jan 1;66(1):283-9 - PubMed
  112. Cancer. 2016 Oct;122(19):3024-31 - PubMed
  113. J Thorac Oncol. 2013 Aug;8(8):1004-11 - PubMed
  114. Lung Cancer. 2014 Aug;85(2):326-30 - PubMed
  115. Clin Cancer Res. 2015 Feb 15;21(4):907-15 - PubMed
  116. Nat Commun. 2015 Mar 11;6:6377 - PubMed
  117. Lancet. 2016 Apr 30;387(10030):1837-46 - PubMed
  118. Cancer Discov. 2015 Aug;5(8):842-9 - PubMed
  119. PLoS One. 2013 Dec 26;8(12 ):e84700 - PubMed
  120. Pathologe. 2016 Mar;37(2):187-91 - PubMed
  121. Genome Res. 2012 Mar;22(3):436-45 - PubMed
  122. Gene. 1991 Jun 30;102(2):213-9 - PubMed
  123. Lung Cancer. 2014 Jun;84(3):215-21 - PubMed
  124. J Thorac Oncol. 2017 Jan;12 (1):141-144 - PubMed
  125. Mod Pathol. 2013 Nov;26(11):1468-77 - PubMed

MeSH terms

Publication Types